MYTX-589

MYTX-589 (formerly SBT-589) is an investigational, preclinical-stage small molecule designed to target mitochondrial dysfunction in rare neurodegenerative and mitochondrial disorders. Developed by Mighty Therapeutics (formerly Stealth BioTherapeutics), the compound belongs to the SBT-580 series of mitochondrial-targeted therapies. Unlike the company's cardiolipin-binding candidates, MYTX-589 acts through a unique mechanism of action that bypasses deficiencies in Complex I of the mitochondrial electron transport chain, thereby restoring cellular bioenergetics, reducing the emission of reactive oxygen species (ROS), and protecting against iron-mediated cell death. Preclinical studies have demonstrated its potential as a disease-modifying therapy, showing cardioprotective effects, prevention of cardiac hypertrophy, and delayed mortality in mouse models of Friedreich's ataxia cardiomyopathy, as well as therapeutic potential in Leigh syndrome.

Other names

MYTX 589MYTX589MYTX-589SBT 589SBT589SBT-589